Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tibolone is a synthetic steroid hormone used primarily for menopausal hormone therapy, the prevention of postmenopausal osteoporosis, and the treatment of endometriosis. It is taken orally and acts as a tissue-selective estrogen activity regulator. Tibolone itself is pharmacologically inactive but is rapidly converted in the body to three active metabolites with estrogenic (3α-hydroxytibolone, 3β-hydroxytibolone), progestogenic, and androgenic (delta-4-tibolone) properties. These metabolites exert tissue-specific effects by acting as agonists at estrogen receptors (mainly in bone and vaginal tissues), progesterone receptors (preventing endometrial hyperplasia), and androgen receptors (affecting libido, mood, brain, and liver). Unlike traditional estrogens used in menopausal therapy, tibolone does not stimulate endometrial or breast tissue significantly. Its main indications are relief of vasomotor symptoms such as hot flashes and prevention of bone loss after menopause[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tibolone.